J&J licenses LegoChem’s Trop2 ADC for $100M upfront

John­son and John­son’s sub­sidiary Janssen is li­cens­ing a Trop2 di­rect­ed an­ti­body-drug con­ju­gate from South Ko­rea’s LegoChem Bio­sciences in a deal that could be worth as much as $1.7 bil­lion.

Along with a $100 mil­lion up­front cash pay­ment, LegoChem will get an op­tion ex­er­cise pay­ment of $200 mil­lion and po­ten­tial fu­ture mile­stones and tiered roy­al­ties on net sales. Both com­pa­nies will work on an on­go­ing Phase I/II tri­al of the drug can­di­date, LCB84, while J&J will work on clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion af­ter the op­tion ex­er­cise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.